SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-14-144242
Filing Date
2014-04-15
Accepted
2014-04-15 16:37:34
Documents
11
Effectiveness Date
2014-04-15

Document Format Files

Seq Description Document Type Size
1 DEFA14A d703460ddefa14a.htm DEFA14A 32362
2 GRAPHIC g703460notice_pg001a.jpg GRAPHIC 36250
3 GRAPHIC g703460notice_pg001b.jpg GRAPHIC 22109
4 GRAPHIC g703460notice_pg001c.jpg GRAPHIC 3977
5 GRAPHIC g703460notice_pg001d.jpg GRAPHIC 15235
6 GRAPHIC g703460notice_pg001e.jpg GRAPHIC 8006
7 GRAPHIC g703460notice_pg001f.jpg GRAPHIC 2610
8 GRAPHIC g703460notice_pg001g.jpg GRAPHIC 3954
9 GRAPHIC g703460notice_pg001h.jpg GRAPHIC 3090
10 GRAPHIC g703460notice_pg002a.jpg GRAPHIC 7971
11 GRAPHIC g703460notice_pg002b.jpg GRAPHIC 3954
  Complete submission text file 0001193125-14-144242.txt   182658
Mailing Address 1500 WEST PARK DRIVE SUITE 210 WESTBOROUGH MA 01581
Business Address 1500 WEST PARK DRIVE SUITE 210 WESTBOROUGH MA 01581 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36304 | Film No.: 14765381
SIC: 2834 Pharmaceutical Preparations